What specific biotech areas did BioNexus Gene Lab propose for Malaysia-China co-development, and what role does the company envision for Malaysia in ASEAN?

BioNexus Gene Lab CEO Sam Tan proposed Malaysia as an ASEAN execution hub for precision diagnostics, liquid biopsy, and AI-integrated healthcare. The company advocates moving beyond trade to co-development of China-origin biotech innovations, aiming to accelerate their clinical validation and commercialization across Southeast Asia through public markets and strategic partnerships.

What is BioNexus Gene Lab’s stated strategic objective regarding China’s biotech innovations in Southeast Asia?

BioNexus Gene Lab aims to leverage public markets and strategic partnerships to accelerate the clinical validation and commercialization of China-origin biotech innovations across Southeast Asia, positioning Malaysia as a bridge for those ambitions.

Turning Malaysia into a Bridge for China’s Biotech Ambitions

May 29, 2026

BioNexus Gene Lab advocated for deeper Malaysia-China biotech cooperation at the 2026 Economic Cooperation Outlook Forum. CEO Sam Tan proposed positioning Malaysia as an ASEAN hub to accelerate the commercialization of Chinese biotech innovations.

Stock Titan

2026-02-23

BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

2026-03-12

BioNexus Gene Lab Corp. Appoints Dr. Muthu Meyyappan as CCO of Fidelion Diagnostics to Lead VitaGuard™ MRD Commercialization

2026-04-04

BioNexus Gene Lab Corp Stock Drops 3% on Poor Ratings

2026-04-14

BioNexus Gene Lab 10-K: Revenue $7.42M, EPS $(1.61)

2026-05-15

BioNexus Gene Lab Corp Q1 2026 Earnings: Revenue $22.84K, EPS ($0.23)